123 related articles for article (PubMed ID: 36511267)
1. Deciphering intratumor heterogeneity in clear cell renal cell carcinoma utilizing clinicopathologic and molecular platforms.
Vormittag-Nocito E; Mannan R; Wang X; Chinnaiyan A; Zhang Y; Zelenka-Wang S; Cao X; Morgan TM; Hafez K; Vaishampayan U; Abdulfatah E; Chinnaiyan AM; Dhanasekaran SM; Mehra R
Hum Pathol; 2022 Dec; 130():95-109. PubMed ID: 36511267
[TBL] [Abstract][Full Text] [Related]
2. Morphological characteristics of SETD2-mutated locally advanced clear cell renal cell carcinoma: Comparison with BAP1-mutated clear cell renal cell carcinoma.
Takeda K; Bastacky S; Dhir R; Mohebnasab M; Quiroga-Garza GM
Ann Diagn Pathol; 2024 Feb; 68():152223. PubMed ID: 37976977
[TBL] [Abstract][Full Text] [Related]
3. Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma.
Bihr S; Ohashi R; Moore AL; Rüschoff JH; Beisel C; Hermanns T; Mischo A; Corrò C; Beyer J; Beerenwinkel N; Moch H; Schraml P
Neoplasia; 2019 Feb; 21(2):247-256. PubMed ID: 30660076
[TBL] [Abstract][Full Text] [Related]
4. BAP1-Mutated Clear Cell Renal Cell Carcinoma.
Gallan AJ; Parilla M; Segal J; Ritterhouse L; Antic T
Am J Clin Pathol; 2021 Apr; 155(5):718-728. PubMed ID: 33210135
[TBL] [Abstract][Full Text] [Related]
5. BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor.
Eckel-Passow JE; Serie DJ; Cheville JC; Ho TH; Kapur P; Brugarolas J; Thompson RH; Leibovich BC; Kwon ED; Joseph RW; Parker AS
BMC Urol; 2017 Mar; 17(1):19. PubMed ID: 28327121
[TBL] [Abstract][Full Text] [Related]
6. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network.
Hakimi AA; Ostrovnaya I; Reva B; Schultz N; Chen YB; Gonen M; Liu H; Takeda S; Voss MH; Tickoo SK; Reuter VE; Russo P; Cheng EH; Sander C; Motzer RJ; Hsieh JJ;
Clin Cancer Res; 2013 Jun; 19(12):3259-67. PubMed ID: 23620406
[TBL] [Abstract][Full Text] [Related]
7. Genomic profiling of the genes on chromosome 3p in sporadic clear cell renal cell carcinoma.
Togo Y; Yoshikawa Y; Suzuki T; Nakano Y; Kanematsu A; Zozumi M; Nojima M; Hirota S; Yamamoto S; Hashimoto-Tamaoki T
Int J Oncol; 2016 Apr; 48(4):1571-80. PubMed ID: 26891804
[TBL] [Abstract][Full Text] [Related]
8. PBRM1 and BAP1 as novel targets for renal cell carcinoma.
Brugarolas J
Cancer J; 2013; 19(4):324-32. PubMed ID: 23867514
[TBL] [Abstract][Full Text] [Related]
9. Prognostic role of BAP1 in pT1 clear cell carcinoma in partial nephrectomy specimens.
Minardi D; Lucarini G; Milanese G; Montironi R; Di Primio R
Virchows Arch; 2017 Jul; 471(1):99-105. PubMed ID: 28488170
[TBL] [Abstract][Full Text] [Related]
10. BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies.
Piva F; Santoni M; Matrana MR; Satti S; Giulietti M; Occhipinti G; Massari F; Cheng L; Lopez-Beltran A; Scarpelli M; Principato G; Cascinu S; Montironi R
Expert Rev Mol Diagn; 2015; 15(9):1201-10. PubMed ID: 26166446
[TBL] [Abstract][Full Text] [Related]
11. Loss of BAP1 expression in metastatic tumor tissue is an event of poor prognosis in patients with metastatic clear cell renal cell carcinoma.
da Costa WH; Fares AF; Bezerra SM; Morini MA; de Toledo Benigno LA; Clavijo DA; Fornazieri L; Rocha MM; da Cunha IW; de Cassio Zequi S
Urol Oncol; 2019 Jan; 37(1):78-85. PubMed ID: 30446457
[TBL] [Abstract][Full Text] [Related]
12. Bap1 is essential for kidney function and cooperates with Vhl in renal tumorigenesis.
Wang SS; Gu YF; Wolff N; Stefanius K; Christie A; Dey A; Hammer RE; Xie XJ; Rakheja D; Pedrosa I; Carroll T; McKay RM; Kapur P; Brugarolas J
Proc Natl Acad Sci U S A; 2014 Nov; 111(46):16538-43. PubMed ID: 25359211
[TBL] [Abstract][Full Text] [Related]
13. Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy.
Tennenbaum DM; Manley BJ; Zabor E; Becerra MF; Carlo MI; Casuscelli J; Redzematovic A; Khan N; Arcila ME; Voss MH; Feldman DR; Motzer RJ; Benfante NE; Coleman JA; Russo P; Hsieh JJ; Hakimi AA
Urol Oncol; 2017 Aug; 35(8):532.e7-532.e13. PubMed ID: 28408295
[TBL] [Abstract][Full Text] [Related]
14. The Identification of Zinc-Finger Protein 433 as a Possible Prognostic Biomarker for Clear-Cell Renal Cell Carcinoma.
Heyliger SO; Soliman KFA; Saulsbury MD; Reams RR
Biomolecules; 2021 Aug; 11(8):. PubMed ID: 34439859
[TBL] [Abstract][Full Text] [Related]
15. Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma.
Hakimi AA; Chen YB; Wren J; Gonen M; Abdel-Wahab O; Heguy A; Liu H; Takeda S; Tickoo SK; Reuter VE; Voss MH; Motzer RJ; Coleman JA; Cheng EH; Russo P; Hsieh JJ
Eur Urol; 2013 May; 63(5):848-54. PubMed ID: 23036577
[TBL] [Abstract][Full Text] [Related]
16. Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC.
Ibragimova I; Maradeo ME; Dulaimi E; Cairns P
Epigenetics; 2013 May; 8(5):486-93. PubMed ID: 23644518
[TBL] [Abstract][Full Text] [Related]
17. Loss of BAP1 protein expression in the first metastatic site predicts prognosis in patients with clear cell renal cell carcinoma.
Miura Y; Inoshita N; Ikeda M; Miyama Y; Oki R; Oka S; Kondoh C; Ozaki Y; Tanabe Y; Kurosawa K; Urakami S; Kohno T; Okaneya T; Takano T
Urol Oncol; 2017 Jun; 35(6):386-391. PubMed ID: 28284891
[TBL] [Abstract][Full Text] [Related]
18. Molecular genetics of clear-cell renal cell carcinoma.
Brugarolas J
J Clin Oncol; 2014 Jun; 32(18):1968-76. PubMed ID: 24821879
[TBL] [Abstract][Full Text] [Related]
19. Extensive intratumor regional epigenetic heterogeneity in clear cell renal cell carcinoma targets kidney enhancers and is associated with poor outcome.
El Khoury LY; Pan X; Hlady RA; Wagner RT; Shaikh S; Wang L; Humphreys MR; Castle EP; Stanton ML; Ho TH; Robertson KD
Clin Epigenetics; 2023 Apr; 15(1):71. PubMed ID: 37120552
[TBL] [Abstract][Full Text] [Related]
20. The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer.
Liao L; Testa JR; Yang H
Cancer Genet; 2015 May; 208(5):206-14. PubMed ID: 25873528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]